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mapped to MedDRA Preferred Terms with BioPortal and ICD9Data.com. Focus was 
limited to EudraVigilance Important Medical Event ADRs. Evaluate Pharma (evalu-
ategroup.com) provided usage data. From January 2011 through December 2013, 
either the most costly “primary suspect” ADR or outcome cost was assigned to each 
case report. Individual report costs were summed for each drug and then divided 
by exposure rates to obtain downstream costs per patient. Eight drugs prescribed 
to treat multiple sclerosis (MS) were analyzed in detail. RESULTS: From lowest to 
highest, average downstream costs per patient exposed were: glatiramer acetate 
($86); dalfampridine ($248); interferon beta-1b ($404); dimethyl fumarate ($552); 
fingolimod ($563); interferon beta-1a (Avonex) ($1,045); interferon beta-1a (Rebif) 
($1,419); and natalizumab ($2,345). It should be noted that under reporting to FAERS 
may result in under estimation of the costs above. CONCLUSIONS: Post-marketing 
ADRs and poor outcomes represent a significant safety issue and cost burden for 
the healthcare industry. The method outlined here used post-marketing data and 
specific cost estimates to compare serious side effect costs across MS drugs. Future 
work may include analyzing other drug classes and using claims data for ADR and 
outcome frequency estimates.
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OBJECTIVES: Compare patient characteristics and frequency of diagnoses between 
high-cost and non‒high-cost MS patients receiving DMDs. METHODS: MS patients 
(aged 18–63; ≥ 1 MS diagnosis claim:ICD-9-CM:340.xx) with ≥ 1 DMD claim (first 
claim= index date) and continuous eligibility 12 months pre- and post-index were 
identified from a random sample of 5 million lives in the IMS LifeLink Plus database 
from 1/1/2007–6/30/2012. Patients with all-cause total costs (excluding DMD costs) 
≥ 75th percentile were considered high-cost. Diagnoses potentially associated 
with costs (“condition indicators”) were grouped into three domains: MS-related 
conditions (e.g., disability), Clinical Classification System (CCS) code categories 
(e.g., gastrointestinal), Charlson-Deyo comorbidities. Fisher and Wilcoxon tests 
were used in unadjusted statistical comparisons. Logistic regression was used to 
evaluate likelihood of being a high-cost patient. Covariates included demograph-
ics, condition indicators, dalfampridine use, newly initiating DMDs and adher-
ence. RESULTS: Analysis included 24,815 patients. 75th percentile for high-cost 
status was $11,740, yielding 6207 high-cost and 18,608 non‒high-cost patients 
(mean age:46.3 vs 44.2, respectively; p< 0.001). In unadjusted analyses, percentage 
of patients with each condition indicator was statistically significantly higher in 
the high-cost group (p< 0.05). In logistic regression analyses, age and sex were 
not consistently predictive of being high-cost. High counts of conditions within 
each domain (e.g., ≥ 5 MS-related conditions: odds ratio [OR]:5.801; p< 0.0001) and 
selected individual conditions (e.g., disability: OR:1.809; p< 0.0001) were associ-
ated with significantly higher likelihood of being high-cost. Dalfampridine use, 
a symptomatic agent, was also significantly associated with being high-cost 
(OR:5.744–6.062 across specifications; p< 0.0001). Conversely, better adherence 
(medication possession ratio ≥ 80%) and newly initiating DMDs were associated 
with lower likelihood of being high-cost (OR:0.570–0.594 and 0.850–0.898 across 
specifications, respectively; all p< 0.01). CONCLUSIONS: MS-related conditions, 
CCS categories and Charlson-Deyo comorbidities were independently associated 
with high costs. Interventions targeting individuals affected by key conditions 
may be important for reducing costs and disease burden.
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OBJECTIVES: Generalized convulsive seizures (GCS), including clonic, myoclonic, 
and tonic-clonic seizures, account for 40% of epilepsy seizures. Patients with GCS, 
especially uncontrolled disease, may accrue significant healthcare resource utiliza-
tion and associated costs. These parameters were estimated in adult patients with 
GCS. METHODS: Adults (≥ 18 years) with ≥ 2 GCS claims (ICD-9 code: 345.1x) 30 days 
apart during index year were identified from OptumInsight® claims database (2011-
2013). Continuous enrollment in their US healthcare plan (medical and pharmacy 
benefit) for ≥ 1 year before and after index date was required. Eligible patients were 
categorized as having stable disease (no change in anti-epileptic drug [AED] over 
12 months) or uncontrolled disease (added AED to an existing regimen). Index date 
was selected during calendar year 2012 (stable disease, convenience date; uncon-
trolled disease, date of additional AED initiation). Pharmacy and medical claims 
during post-index year were used to estimate overall and epilepsy-related resource 
utilization and costs. Analysis of covariance was used to compare outcomes after 
adjusting for baseline differences between groups. RESULTS: Annual estimates 
were based on 1,201 patients (1,067 stable/134 uncontrolled): mean age, 40 years; 
female sex, 54%/55%; and mean Charlson comorbidity index, 0.70/0.90. Inpatient 
and outpatient ER rates were 15.6% (epilepsy-related 10.6%) and 32.0% (epilepsy-
related 15.9%) for stable patients, and 23.9% (epilepsy-related 22.4%) and 42.5% 
(epilepsy-related 27.6%) for uncontrolled patients. Associated mean costs were 
substantially less for stable ($16,487; epilepsy-related, $6,570) than uncontrolled 
($30,648; epilepsy-related, $16,102) patients. After adjusting for baseline characteris-
tics, the difference was significantly less: $10,928 (P= 0.0006); epilepsy-related $8,769 
(P< 0.0001). CONCLUSIONS: Patients with uncontrolled GCS accrue significantly 
more healthcare resource utilization. Uncontrolled GCS patents have considerably 
higher costs for both total and epilepsy related than stable patients (39%, total 
overall annual costs, 57%, epilepsy related). Early and effective disease manage-
ment of patients with uncontrolled GCS may mitigate the high economic burden.
estimated budget impact of adding peginterferon beta-1a to the formulary was 
negative for the first 5 years: in 2014, with a treatment share of 3.0%, the estimated 
budget decrease was 0.07% of the total annual costs for DMT-related and relapse 
treatment costs and a decrease of $0.005 per member per month (PMPM); in 2018, 
with a treatment share of 7%, the estimated budget decrease was 0.23% of the 
total annual costs and a decrease of $0.014 PMPM. Sensitivity analyses showed 
that the model was most sensitive to the acquisition costs of peginterferon beta-
1a. CONCLUSIONS: Under model assumptions for market shares, adding peginter-
feron beta-1a to the MCO formulary would result in a small decrease in MCO costs 
for patients with relapsing forms of MS.
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OBJECTIVES: To estimate the budget impact of sugammadex within a typical US 
hospital. METHODS: A model was developed to evaluate budget impact of using 
sugammadex instead of neostigmine or spontaneous reversal in a subset of hospital 
procedures. Sugammadex utilization was projected to be highest in procedures 
with deep neuromuscular block (NMB) throughout, and patients at elevated risk of 
post-operative respiratory complications. Inputs included costs of NMB and reversal 
agents, operating room (OR) procedure time, value of OR time, risks and costs of 
residual neuromuscular blockade (RNMB) and associated complications, and reduc-
tions in RNMB with sugammadex use. Because trials have shown sugammadex’s 
impact on OR time and RNMB varies by whether full neuromuscular recovery (train-
of-four [TOF] ratio ≥ 0.9) is verified prior to extubation in the OR, two scenarios were 
modeled, evaluating when recovery to TOF ≥ 0.9 is verified prior to extubation and 
when it is not. RESULTS: When all patients are verified to have full neuromuscular 
recovery (TOF ≥ 0.9, no RNMB) prior to extubation, sugammadex saved an average 
of 24 minutes in the OR per procedure, with a net cost savings provided at least 10% 
of OR time saved can be converted to increased throughput. When no patients are 
verified to have full recovery prior to extubation, sugammadex saved 1 minute in the 
OR per procedure; while reducing the risk of RNMB from 47% to 3%. The incidence of 
post-operative aspiration, hypoxemia, muscle weakness or upper airway obstruction 
was reduced from 86 per 100 procedures, to 36 per 100 among patients receiving 
sugammadex, at an average incremental cost of $66 per procedure. CONCLUSIONS: 
Budget impact of sugammadex was found to vary according to practices for neu-
romuscular monitoring and extubation. Use of sugammadex can ameliorate the 
current trade-off between OR efficiency and occurrence of RNMB when utilizing 
neostigmine or spontaneous reversal.
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OBJECTIVES: Currently the clinical protocols for the treatment of relapsing-
remitting multiple sclerosis of the public sector in Brazil do not differentiate the 
interferonβ options available (Avonex®, Betaferon® or Rebif®). Considering the data 
presented in a meta-analysis by Filippini et al in 2013, a budget impact analysis 
was developed to understand the impacts of recommending the use of Rebif® as 
the interferon of choice. METHODS: A transition model was developed under the 
assumption that patients experiencing a relapse would have a 50% chance of switch-
ing to another line of therapy. Each treatment relapse rate was calculated from the 
Philippini 2013 meta-analysis information regarding the risk of having a relapse 
in 24months, using the formulae developed by Zhang and Yu, 1998. Such formula 
calculates the relative risk from odds ratio information using the “assumed control 
risk”, which was calculated by the pondered average rate of relapses occurring in 
all related trials’ placebo arms. Only 2014 direct medical costs were considered, 
including medications and hospital costs obtained at the DATASUS database. The 
number of patients was estimated by the number of treatments provided at the year 
of 2014, and the time horizon was defined as 5 years. Market shares were calculated 
from the 2014 public purchases information and the compared scenarios were the 
current practice versus an alternative scenario where Rebif® was considered the 
interferon of choice. RESULTS: Current scenario represents BRL1,288.32 million 
in first and second line medications, BRL219.00 million in third line medications, 
and BRL20.46 million in relapses’ acute care. Alternative scenario could represent 
BRL1,300.51 million in first and second line medications, BRL201.16 million in third 
line medications and BRL19.94 million in relapses’ acute care. CONCLUSIONS: Total 
savings with the new scenario were BRL 6.16 million, mainly by reducing relapses 
and delaying the start of more expensive third line medications.
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OBJECTIVES: Adverse Drug Reactions (ADRs) and outcomes observed during homog-
enous pre-approval clinical trials frequently do not correlate with real-world expe-
rience. The substantial costs associated with ADRs and poor outcomes represent 
a significant burden to the healthcare system. Frequency estimates coupled with 
specific ADR and outcome costs may provide a way to compare downstream impact. 
This study sought to estimate the post-marketing costs associated with ADRs and 
outcomes for individual drugs by combining: 1) ADR and outcome-specific costs, 2) 
data from the FDA’s Adverse Event Reporting database (FAERS), and 3) drug usage 
information. METHODS: ADR and outcome data were obtained from FAERS. ADR 
and outcome costs were obtained from AHRQ. ICD-9 codes for ADR costs were 
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OBJECTIVES: Epilepsy is common chronic disorder characterized by recurrent 
unprovoked seizures with incidence rate of 20 to 70 per 100 000 population per 
year. Approximately 150,000 children sustain a first-time unprovoked seizure every 
year, and of those, 30,000 develop epilepsy. To evaluate the economic burden of pedi-
atric epileptic patients and cost of their epilepsy management from the patients’ 
perspective. METHODS: This study adopted a prospective cross sectional design by 
interviewing the patient’s parents from neurology clinic of Hospital Pulau Pinang, 
Malaysia. A retrospective data (for the past 12 months) was collected from patient’s 
medical record for the laboratory test, investigations and treatment received. The 
collected data included information about the patient’s resources utilization, lost 
productivity, and out of pocket expenditure. RESULTS: Majority of respondent was 
male which comprise of 64.2% whereby female was 35.8%. Mean (±SD) total annual 
cost from patient perspective was RM 1303.05 ± 2288.66 (USD 366.69±644.06) per 
patient. The highest item cost which contributes to the total annual cost was the 
loss of productivity which is RM 528.26 ± 786.22 (USD 148.66±221.25) followed by cost 
of caretaker RM 690.32 ± 1929.41 (USD 194.26±542.96) and meal/snack cost during 
clinic visit RM 44.97±56.87 (USD 12.66±16). The lowest contributor for annual cost 
from patient perspective was transportation cost with a mean of RM 39.51 ± 31.73 
(USD 11.22±8.93). CONCLUSIONS: In conclusion, from patients’ perspectives loss of 
productivity is the major contributor in economic burden to epilepsy management 
in pediatric. Type of seizure associated with neurological deficit and the response 
to the medication which affects the number of clinic visit, number of hospitaliza-
tion and length of hospital admission influence lifetime cost of epilepsy bear by 
the patient depending on employment and monthly incomes as well as who is the 
caretaker and who bring the child to clinic visit and accompanied the child during 
hospital admission.
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OBJECTIVES: No recent study on the medical costs of multiple-sclerosis (MS) 
has employed real world data to analyze relapsing-remitting multiple sclerosis 
(RRMS) and primary progressive multiple sclerosis (PPMS). This paper analyzes 
the medical costs of RRMS to identify the causes of the high medical costs of 
MS. METHODS: We selected subjects from among active employees and their fam-
ilies who were covered by private health insurance from MedStat Commercial Data 
from 2005 to 2012. We developed logic to identify MS patients, MS relapses and 
RRMS patients and PPMS patients with claims data. The PPPM of RRMS patients 
was analyzed in cases where relapsing intervals were greater than the average 
interval length. RESULTS: The PPPM of RRMS patients was $4,964 PPPM. The fre-
quency of RRMS relapses was 3.2 times during 5 years. The PPPM of RRMS patients 
was reduced by $958 PPPM when relapsing intervals were increased by 1.2 times 
compared to the usual RRMS relapsing intervals. The PPPM of RRMS patients was 
reduced by $1,139 PPPM when relapsing intervals were increased by 1.5 times 
compared to the usual RRMS relapsing intervals. CONCLUSIONS: The number 
of RRMS patients among MS patients was 87 %. The PPPM of relapses accounted 
for 83% of PPPM of RRMS. By restricting the frequency of relapses it is possible to 
reduce the PPPM of RRMS patients.
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OBJECTIVES: To evaluate the health care resource utilization and costs 
among patients diagnosed with chronic migraine (CM) in the Veterans Health 
Administration (VHA) medical dataset. METHODS: Patients diagnosed with CM 
were identified (International Classification of Diseases, 9th Revision, Clinical 
Modification diagnosis code 346.XX) using the VHA dataset from October 1, 2008 
through September 30, 2010. The initial diagnosis date was designated as the index 
date. Patients without CM with the same age, gender and region (comparison cohort) 
were matched using a randomly chosen index date to minimize selection bias. 
Patients in both cohorts were at least age 18 years and had continuous medical 
and pharmacy benefits for 1 year before and after the index date. One-to-one pro-
pensity score matching (PSM) was used to compare health care costs and utiliza-
tions between the CM and the comparison cohorts, and was adjusted for baseline 
demographic and clinical characteristics. Pain scores were also included to investi-
gate wellness after CM diagnosis. RESULTS: After risk-adjustment by PSM, 123,241 
patients in each cohort were matched. Significantly more CM patients had inpatient 
admissions (6.44% vs. 1.75%, p< 0.0001) and emergency room (ER; 14.42% vs. 5.50%, 
p< 0.0001), outpatient office (68.80% vs. 42.15%, p< 0.0001), outpatient (69.30% vs. 
42.91%, p< 0.0001) and pharmacy visits (70.84% vs. 41.43%, p< 0.0001) compared to 
those without CM. Accordingly, CM patients also incurred higher costs for inpa-
tient admissions and ER, office, outpatient and pharmacy visits compared to those 
without CM. Total costs incurred by CM patients were $4,776, almost triple that of 
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OBJECTIVES: To assess the trends in average wholesaler prices at market entry for 
multiple sclerosis (MS) disease-modifying therapies (DMTs) approved by the US 
Food and Drug Administration (FDA) in the period 1987-2014. METHODS: DMTs 
regulatory information was derived from the FDA website. Average wholesaler 
prices (AWP) per unit at market entry data were derived from the RedBook (Truven 
Health Analytics, Inc.). The AWP history was collected from year of approval to 
October 2014. The daily defined dosage (DDD) for adult patients was obtained 
from FDA approved labels. AWP per DDD and the AWP per year were computed. 
Descriptive statistics and Wilcoxon tests were performed. Statistical significance 
level was set at 0.05. RESULTS: The National Multiple Sclerosis Society listed 11 
FDA approved DMTs (5 new drug applications [NDA] and 6 biological license appli-
cations [BLA]) as of October 2014. Two products were approved by the FDA using 
priority review. The FDA granted orphan designation to 5 DMTs. Only one DMT 
had generic competition in the study period. There was one DMT approved by US 
FDA in the 1980s, three in the 1990s and 2000s, respectively, and 4 in the period 
2010-2014. The median AWP per DDD was $5.88 in the 1980s, $7.13 in the 1990s, 
$217.52 in the 2000s, and $274.76 in the period 2010–Oct 2014. Statistically signifi-
cant differences were found in median AWP per DDD prices between NDAs and 
BLAs. The median AWP per DDD was not significantly different for FDA priority 
review drugs compared to standard review drugs, and for orphan compared to 
non-orphan drugs. CONCLUSIONS: The median AWP per DDD for DMTs at market 
entry increased substantially over time. No statistically significant differences 
were found in the median AWP per DDD between priority and standard review 
drugs, and between orphan and non-orphan drugs.
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OBJECTIVES: To evaluate the economic consequences of having spinal muscular 
atrophy (SMA). METHODS: This study was conducted using Department of Defense 
Military Healthcare System (MHS) data from 2003 to 2012. Eligible persons had a 
SMA diagnosis (ICD-9CM codes 335.0 or 335.1) on 1 inpatient or 3 outpatient claims 
before 18 years of age. Individuals had at least 6 months of data after first SMA 
diagnosis; or died within 6 months after first SMA diagnosis; or had at least 12 
months of data before first SMA diagnosis. Subgroup analyses were conducted for 
early (≤1 years) and late diagnosis (>1 years). RESULTS: A total of 239 individu-
als met the inclusion criteria. The median total expenditure, while enrolled in the 
MHS, was $83,652 (25-75 percentile $29,620-$228,754) over a mean observation of 
6.9±3.6 years, though rare outlier costs were as high as $4.4 million. The mean age 
(SD) at first observed SMA diagnosis was 7.5±6.4 years. The mean (SD) duration of 
observation following initial SMA diagnosis was 4.8±3.3 years with a median cost 
of $60,213 ($18,229-$192,559). For all patients, the primary cost driver was outpa-
tient costs (median $53,152 ($23,902-$136,150)), followed by inpatient costs (median 
$11,258 ($0-$51,987)) and total prescription costs (median $3,167 ($943-$13,283)). 
The subgroup of patients with early diagnosis (n=45) had 4.3±2.9 years of observa-
tion with a median cost of $167,921 ($53,349-$678,412)). Approximately 17.8% of 
this subgroup died during the observation period, which highlights the devastating 
nature of early onset SMA. Patients with late diagnosis (n=194) had 7.5±3.4 years 
observation and median total costs of $70,380 ($28,196-$184,272). CONCLUSIONS: 
Individuals with SMA have a high degree of morbidity and mortality, particularly 
those diagnosed during infancy. SMA patients have significant medical expenditures 
and high utilization of health care services. There is significant economic burden 
caring for patients diagnosed with SMA. DISCLAIMER: Research derived from an IRB 
approved protocol at Naval Medical Center Portsmouth, VA. The views expressed in 
this abstract are those of the authors and do not necessarily reflect the official policy 
or position of the Department of the Army, Department of the Navy, Department of 
Defense or the United States Government. George J. Dahl and Rees Lee are members 
of the U.S. military. This work was prepared as part of their official duties. Title 17 
U.S.C. 105 provides that ‘Copyright protection under this title is not available for any 
work of the United States Government.’ Title 17 U.S.C. 101 defines a United States 
Government work as a work prepared by a military service member or employee of 
the United States Government as part of that person’s official duties.
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